Overview

CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

Status:
RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of CMV-specific T cell immunity test in prolonged usage of letermovir for avoiding late-onset csCMVi after all-HSCT.
Phase:
NA
Details
Lead Sponsor:
Ruijin Hospital
Treatments:
letermovir